Načítá se...
Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials
We reviewed all fully published clinical trials assessing anti-angiogenic agents in sarcoma patients (last issue, January 13, 2020). Anti-angiogenic macromolecules (e.g., bevacizumab or ombrabulin) provide disappointing results. Many multikinase inhibitors have been assessed with non-randomized phas...
Uloženo v:
| Vydáno v: | Front Oncol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7732617/ https://ncbi.nlm.nih.gov/pubmed/33330082 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.594445 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|